~~<i id='E5A85A5C13'><strike id='E5A85A5C13'><tt id='E5A85A5C13'><pre id='E5A85A5C13'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：knowledge 2025-09-02 06:40:55 - browse：751

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Questions loom on AstraZeneca cancer drug as safety concerns ebb

Wikipedia

hotspot

knowledge

focus

MollyFerguson/STATTheFoodandDrugAdministrationshouldhaltCassavaSciences’ongoingclinicaltrialsinAlzhe

WSS

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Is there really a nursing shortage in the U.S.?

The world needs the new pandemic treaty

Roche drug slashes death risk in early

How AI can help patients find reliable information about doctors

focus

fashion

Wikipedia

Heart attack and stroke risk calculators need revising

Medical students need to learn the potent medicine of empathy

What does generative AI mean for health care? We asked experts

Is there really a nursing shortage in the U.S.?

Moonlake's readout produced a cash windfall. Risks remain

Why a market frenzy over new weight loss drugs defies logic

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Clinicians often fail to acknowledge the pain caused by long Covid

After affirmative action ruling, medical educators look to 'holistic review'

Results on Novartis prostate cancer therapy could expand its use

Wikipedia

Pharma’s losing bet in New Jersey

Study on Amgen’s bispecific immunotherapy produces positive data

STAT Summit: Meghan O’Rourke on making chronic illness visible

Beyond aggravation: Constipation is an American epidemic

Is there really a nursing shortage in the U.S.?

Should insurance cover cosmetic surgery?

hotspot

hotspot

knowledge

focus